Skymount Medical

Skymount Medical announced today that it has achieved a significant milestone with the recent approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a human clinical trial of its novel oral therapeutic for patients with mild to moderate COVID-19. Read the full announcement here: https://bit.ly/3p8kaKC

LSU LSU Research

Skymount Medical Receives UK MHRA Approval to Test New Treatment in Patients with Mild to Moderate COVID-19 -- MHRA grants permission for UK clinical trials for AI-discovered drug combination that reduces length and severity of symptoms and could lower...

Listen to our Chief Executive Officer and Chief Medical & Scientific Officer as they discuss clinical trials, breakthroughs on COVID-19 treatments, and how AI tech is disrupting drug discovery and development, in an earlier interview with Danielle Smith, President of Alberta Enterprise Group.
Check it out here: https://youtu.be/lFsT4BUxYhc

An Interview with Skyview Medical Join Danielle Smith and executives from Skyview for a discussion on clinical trials and medical innovation

New Flash | Skymount Medical has partnered with Riverside University Health System (RUHS) Medical Center to conduct the first U.S. clinical trial on the efficacy of COVID-19 oral therapeutics discovered by Louisiana State University researchers using artificial intelligence.

Read the full press release at: https://skymountmed.com/2021/11/03/riverside-university-health-system-medical-center-skymount-medical-begin-u-s-clinical-trial-for-covid-19-oral-therapeutics-discovered-using-artificial-intelligence/